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might indicate a functional relevance of these cells in the re-
spective entities. Since increased numbers of PD-1+ cells 
outside GC are observed in various LA, this finding might not 
be entirely specific for pattern I AITL. 
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 Introduction 
 Programmed death-1 (PD-1) is a member of the CD28 
costimulatory receptor superfamily. It is expressed on a 
subset of thymocytes and is upregulated on activated T, 
B and myeloid cells. Dorfman et al.  [1] found that PD-1 is 
specifically expressed by germinal center (GC)-associat-
ed T cells in reactive lymphoid tissue as well as by tumor 
cells in angioimmunoblastic T-cell lymphoma (AITL).
 PD-1 inhibits T-cell activity via a negative signal to T 
cells in conjunction with signaling through the T-cell re-
ceptor. Recent studies indicate that PD-1 functions as a 
negative regulator of the immune system and is impor-
tant in peripheral tolerance  [2] . There are at least two li-
gands for PD-1, PD-L1 and PD-L2. PD-L-PD-1 interac-
tions lead to cell cycle arrest in G 0 /G 1 but do not increase 
cell death. PD-L1 engagement of PD-1 on T cells inhibits 
activation of these cells. Engagement of PD-1 by PD-L2 
dramatically inhibits T-cell receptor-mediated prolifera-
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 Abstract 
 Objectives: Programmed death-1 (PD-1) is physiologically 
expressed by germinal center (GC)-associated helper T cells. 
It has been proposed that an increase in PD-1+ cells outside 
GC could indicate pattern I angioimmunoblastic T-cell lym-
phoma (AITL).  Methods: We studied the distribution of PD-
1+ cells in reactive lymphadenopathies (LA), including HIV-
associated and dermatopathic LA (n = 5, each), Castleman 
(n = 3), Kikuchi (n = 2) and Rosai-Dorfman diseases (n = 1), 
sarcoidoses (n = 7) and follicular hyperplasias (n = 8).  Results: 
The highest concentrations of PD-1+ cells in GC were found 
in Castleman and Rosai-Dorfman diseases (mean 57 and 
50% of total cells, respectively), and the lowest in HIV-associ-
ated LA (mean 6%). The highest proportions in paracortices 
were found in Castleman disease, and in HIV-associated and 
dermatopathic LA (mean 7, 3 and 2%, respectively). PD-1+ 
cells predominated in the pale zones of GC in follicular hy-
perplasia. In HIV-associated LA, PD-1+ cells showed marked 
marginalization in the GC. No paracortical PD-1+ cells were 
found in sarcoidoses and Rosai-Dorfman disease.  Conclu-
sions: The varying distribution of PD-1+ cells in defined LA 
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tion and cytokine production by CD4+ cells  [3] . It has 
been shown that PD-1 is selectively upregulated by ex-
hausted T cells during chronic viral infection such as 
HIV. Blockade of PD-1-related pathways restores CD8+ 
T-cell functions and reduces viral load  [4] .
 It has been proposed that an increase in PD-1+ cells 
outside GC could be a precursor lesion of AITL  [5, 6] . The 
aim of our study was to determine the distribution of PD-
1+ cells, particularly their appearance outside GC, in var-
ious reactive lymphadenopathies (LA).
 Material and Methods 
 Thirty-one samples of various LA were collected from the ar-
chives of the Institute of Pathology at the University Hospital of 
Basel. All were reevaluated and the initial diagnosis was con-
firmed: dermatopathic LA (n = 5), Castleman disease of the hya-
line-vascular type, all HIV negative (n = 3), Kikuchi disease (n = 
2), Rosai-Dorfman disease (n = 1), HIV-associated LA (n = 5), sar-
coidoses (n = 7) and follicular hyperplasias (n = 8).
 Immunohistochemistry 
 Immunohistochemical staining of formalin-fixed and paraf-
fin-embedded tissue was performed. Slides were stained manu-
ally. Heat-induced (autoclave) antigen retrieval in citrate buffer 
(pH 6.0) for 10 min at 120 ° C was performed and the streptavidin-
biotin-peroxidase detection technique was applied with amino-
ethylcarbazole  as  chromogen.  The  primary  goat   anti-human  
PD-1 antibody (AF 1086; R & D Systems, Germany) was diluted 
1: 40 in a 1% solution of bovine serum albumin in PBS (pH 7.4) and 
the slides were incubated overnight at 4 ° C. The percentage of PD-
1+ cells in relation to all background cells in different lymph node 
areas was determined considering at least 5 microscopic fields 
(5  ! 1.33 mm 2 ) at 200-fold magnification. Scoring was per-
formed on a double-headed microscope by two of us (S.M. and 
A.T.). Reproducibility was assessed by rescoring of the samples by 
one of us (A.T.) and estimated by interclass correlation coeffi-
cients, using reliability analysis (Cronbach’s   ).
 Results 
 PD-1+ cell quantization was reproducible (average in-
terobservation correlation coefficient 0.92), being excel-
lent (  = 1) in samples with fewer PD-1+ cells, e.g. sar-
coidoses, Kikuchi and Rosai-Dorfman diseases, and good 
(  = 0.84) in HIV-associated and dermatopathic LA. The 
distribution of PD-1+ cells varied considerably between 
the different reactive LA ( table 1 ;  fig. 1 ). The highest per-
centages of PD-1+ cells in GC were found in Castleman 
and Rosai-Dorfman disease (mean 57 and 50% of total 
cells, respectively), and the lowest percentage in HIV-as-
sociated LA (mean 6%). The highest percentage in para-
cortices near the mantle zones were found in Castleman 
disease, and HIV-associated and dermatopathic LA 
(mean 7, 3 and 2%, respectively). PD-1+ cells were located 
between monocytoid B cells in hyperplastic marginal 
zones, between Langerhans’ cells in dermatopathic LA 
and in the pale GC zones in follicular hyperplasia. In 
HIV-associated LA, PD-1+ cells showed a marked mar-
ginalization in GC. No PD-1+ cells were found in the 
paracortices of lymph nodes with sarcoidosis and Rosai-
Dorfman disease and in the necrosis zones of Kikuchi 
disease.
 Discussion 
 In our study, we demonstrate varying distribution of 
PD-1+ cells in defined LA. Clusters of PD-1+ neoplastic 
cells in perifollicular areas and around high endothelial 
venules in the expanded paracortex of lymph nodes have 
been proposed as a diagnostic criterion for pattern I AITL 
 [1, 5, 6] . However, since markedly increased numbers of 
PD-1+ cells are also found in the paracortex of lymph 
Table 1. Distribution of PD-1+ cells in reactive LA




Castleman disease 57820 10817 7811
Dermatopathic LA 2585 180.8 282 scattered between monocytoid cells
Follicular hyperplasia 22821 182 182 abundant in pale zones of GC
HIV-associated LA 684 783 381 marked marginalization in GC
Kikuchi disease 2384 686 0.380.4 absent in necrosis zones
Rosai-Dorfman disease 50 2 0


























   
   
   
   
























nodes with Castleman disease, and HIV-associated and 
dermatopathic LA, this finding should not be regarded as 
absolutely specific for pattern I AITL and these three con-
ditions might be of relevance to be considered in the dif-
ferential diagnosis. Beyond presence of PD-1+ cell clus-
ters outside GC, the diagnosis of pattern I AITL should 
be corroborated, as suggested by Rodriguez-Justo et al. 
 [6] , by the typical morphological appearance and pres-
ence of Epstein-Barr virus-infected B (immuno)blasts. 
Since Castleman disease and AITL are accompanied by 
immune control deregulation  [7, 8] , the increased num-
bers of extrafollicular PD-1+ cells in the former, analo-
gously to the neoplastic PD-1+ cells of AITL, might be of 
functional relevance in that instance.
 In HIV-associated LA, the number of PD-1+ cells in 
GC was low, with a marked marginalization beneath the 
mantle zones. Recent data show that PD-1 is significant-
ly upregulated on killer T cells that recognize HIV anti-
gens in the peripheral blood of HIV-infected patients. 
This seems to exhaust T cells, which no longer perform 
vital functions to control viral infection  [9] . While the 
proportion of killer T cells expressing PD-1 is markedly 
increased in the peripheral blood of HIV-infected pa-




 Fig. 1.  a PD-1+ cells in a hyperplastic GC of follicular hyperplasia. Note the abundance 
of PD-1+ cells in the pale zone.  ! 100.  b PD-1+ cells in a typical small involuting GC of 
hyaline-vascular Castleman disease. Note the persistence of PD-1+ cells despite GC B-
cell depletion, and their increased numbers in mantle zones and the paracortices near 
the mantle zones.  ! 160.  c Marked depletion inside and marginalization of PD-1+ cells 
beneath the mantle zones of hyperplastic GC of HIV-associated LA type A.  ! 80.  d In-
creased numbers of PD-1+ cells between monocytoid cells in hyperplastic marginal 
zones and between Langerhans cells in dermatopathic LA.  ! 100. No PD-1+ cells in
the paracortex of lymph nodes with Rosai-Dorfman disease ( e ), in necrotic zones of 
Kikuchi disease ( f ) and in sarcoidosis ( g ). Note retained PD-1+ cells in regressed GC. 
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follicular marginalization beneath the mantle zones of 
the PD-1+ T-follicular helper cells in HIV-associated LA. 
The functional importance of these PD-1+ cell redistri-
bution patterns, though likely being of relevance, e.g. for 
abnormal B-cell function in HIV infection  [10] , remains 
to be elucidated.
 While there is a general increase in the CD4+/CD8+ 
ratio in lymph nodes in sarcoidosis, this increase does not 
apply to the PD-1+ (CD4+) T cells in the T-cell zones. 
Since PD-1+ T cells have an inhibitory effect on other T 
cells, this lacking increase in PD-1+ cells in the paracor-
tices could be of relevance for the expansion of other 
CD4+ T cells, e.g. in granuloma formation  [11] .
 To summarize, the varying distribution of PD-1+ cells 
in defined LA could indicate their functional relevance 
in the respective entities. Since increased numbers of
PD-1+ cells outside GC are also found in various LA, this 
finding is not entirely specific for pattern I AITL. 
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